Navigation Links
CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Date:8/20/2008

matoid Arthritis vaccine."

About Multikine:

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

CEL-SCI is currently building a manufacturing facility for Multikine close to Baltimore, MD. Upon completion of the facility in the 3rd quarter of 2008, CEL-SCI will commence the Phase III clinical trial. Multikine appears to be the first non-toxic cancer drug.

Multikine, a patented defined mixture of naturally derived cytokines, is the first immunotherapeutic agent in a new class of drugs called "Immune SIMULATORS". Immune SIMULATORS simulate the way our natural immune system acts in defending us against cancer. As opposed to other immunotherapies which are designed to target a single or limited number of specific antigens or molecules, Immune SIMULATORS are multi-targeted; they simultaneously cause a direct and targeted killing of the specific tumor cells and they activate the immune system to produce a stronger anti-tumor attack on multiple fronts.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit th
'/>"/>

SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI to Present at the Noble Financial Conference
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
6. MannKind Corporation Reports Second Quarter Financial Results
7. Genaera Corporation Announces Second Quarter Financial Results
8. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
9. Pharmos Corporation Reports 2008 Second Quarter Results
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
(Date:9/18/2014)... rare diseases that afflict skeletal growth through abnormalities ... the fetal stage and is caused by genetic ... growth factor receptor 3 (FGFR3) has been associated ... (TD), a skeletal dysplasia that cause serious respiratory ... achondroplasia (ACH), which causes stunted growth and other ...
Breaking Biology Technology:Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 21974 - 2014 - Mapi fĂȘte ses 40 ans 2Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... Directors,of Eli Lilly and Company (NYSE: LLY ) ... December 1, 2008. Oberhelman, 55, currently serves as,a group ... Caterpillar,s,executive office. As a member of Lilly,s board, Oberhelman ... committee. He will stand for,election by Lilly shareholders at ...
... KANNAPOLIS, N.C., Oct. 20 Academia, science, industry,and ... at 10,AM at the Dedication and Open House ... the UNC Nutrition Research Building and the NC,State ... Nutrition,Research Building is home to NC A&T University, ...
... Recruitment, and Employment Branding joins Pierpoint International as Global VP of ... ... (PRWEB) October 20, 2008 -- Pierpoint International is pleased to announce ... and Diversity. Mr. Cantu, most recently served as AVP of Staffing ...
Cached Biology Technology:Douglas Oberhelman Elected to Lilly Board of Directors 2Douglas Oberhelman Elected to Lilly Board of Directors 3Campus Celebrates Historic Milestone 2Campus Celebrates Historic Milestone 3Campus Celebrates Historic Milestone 4Campus Celebrates Historic Milestone 5Robert Cantu Appointed Vice President of Pierpoint International 2
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
(Date:9/18/2014)... Colo., USA Miranda, a small, icy moon of ... enigmatic bodies in the solar system. Despite its relatively ... of intense resurfacing that resulted in the formation of ... polygonal-shaped regions called coronae. , These coronae are ... at least 200 km across. Arden corona, the largest, ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... MIAMI March 10, 2011 -- Scientists from the University ... were part of a national research team to find two ... Horizon oil spill. In a study published in this week,s ... offers new insight into the mechanism by which the crude ...
... of California, San Francisco (UCSF) has developed a new ... but untreatable and incurable neurodegenerative disease. The disease, frontotemporal ... dementia before age 65, after Alzheimer,s disease. Based ... work explains in part why the brain deteriorates in ...
... New Orleans, LA LSU oncologist Vince D. ... article reporting two chemotherapy drugs now indicated for second ... cancer are remarkably effective in treating a certain subset ... of Medicine at LSU Health Sciences Center New Orleans ...
Cached Biology News:New study reveals aerosol plumes downwind of the Deepwater Horizon oil spill 2UCSF report describes new model for neurodegeneration 2UCSF report describes new model for neurodegeneration 3Study shows new treatment strategy effective for certain lung cancers 2
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
... collects data from balances and scales with RS232 ... other program. If you can type the weight ... collection process Simple to use parser extracts ... , Add user information , Collect data at ...
... collection and automation that is controlled from within ... , Pre-configured library of interfaces for balances, ... be added and configured by the user ... one spreadsheet , Allows for multi-tasking ...
...
Biology Products: